TuHURA Acquires Kineta in Closed Merger

TuHURA Biosciences completed a two-step merger with Kineta on June 30, 2025. Under the merger structure, Merger Sub I merged with and into Kineta, and then the surviving entity merged with and into Merger Sub II, with Merger Sub II as the surviving company.

As a result of the Mergers, TuHURA acquired Kineta, including the rights to Kineta’s novel KVA12123 antibody, which was renamed TBS-2025. The filing states the transaction was accounted for as a business combination using the acquisition method under U.S. GAAP.

The pro forma financial information combines TuHURA’s audited condensed consolidated statement of operations for the year ended December 31, 2025 with Kineta’s unaudited statement for the period ended June 29, 2025, as if the Mergers occurred on January 1, 2025.